Product/Composition:- | Canagliflozin tablets |
---|---|
Strength:- | 100 mg and 300 mg |
Form:- | Tablets |
Reference Brands:- | Invokana(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Canagliflozin, an SGLT2 inhibitor, blocks renal glucose reabsorption, increasing urinary glucose excretion. This lowers blood glucose in type 2 diabetes. Benefits include improved glycemic control, weight loss, reduced blood pressure, and decreased cardiovascular and renal risks, with a low hypoglycemia risk.
Canagliflozin is an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor used for managing type 2 diabetes and reducing cardiovascular and renal risks. Approved by the FDA in 2013 under the brand Invokana (100 mg, 300 mg), it received EU approval via centralized procedure the same year. It may be used as monotherapy or in combination with other antidiabetic agents. Canagliflozin lowers blood glucose by promoting urinary glucose excretion. Periodic renal assessment is recommended. Through Pharmatradz.com, B2B pharmaceutical buyers can source Canagliflozin from globally audited manufacturers and exporters, ensuring compliance with USA FDA and EU EMA regulatory standards.